Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
| العنوان: | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
|---|---|
| المؤلفون: | Wei Wang, G. Wang, X. Yu, Yi-Fu He, Yueyin Pan, Xiaojun Qian, Yubei Sun |
| المصدر: | Clinical and Translational Oncology. 22:813-822 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, Colorectal cancer, Antineoplastic Agents, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Growth factor receptor, Internal medicine, Biomarkers, Tumor, Prevalence, medicine, Humans, HER2 Amplification, skin and connective tissue diseases, neoplasms, PI3K/AKT/mTOR pathway, business.industry, Cancer, General Medicine, Prognosis, medicine.disease, digestive system diseases, ErbB Receptors, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Biomarker (medicine), KRAS, Colorectal Neoplasms, business |
| الوصف: | Numerous inherent and acquired genetic alterations have been demonstrated with resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy in metastatic colorectal cancer (mCRC) patients. Although the common oncogenic driver mutations identified include KRAS, NRAS, BRAF, and PI3K, recent studies report a vital role played by human epithelial growth factor receptor-2 (HER2) amplification in acquired resistance to anti-EGFR therapy. HER2 amplification has been associated with poor prognosis in many malignancies including breast and gastric cancer and is also a negative predictor of anti-EGFR therapy. Given the relevance of HER2 amplification in conferring an anti-EGFR resistance, this paper reviews the prevalence of HER2 amplification in mCRC while exploring the prognostic and predictive values of this biomarker. Further, we also discuss the results of the studies that explored the utilization of anti-HER2-targeted therapies in mCRC. HER2-directed therapies have the ability to change the treatment algorithm in clinically relevant small subset of patients with HER2-amplified mCRC. |
| تدمد: | 1699-3055 1699-048X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eabdbae4f23487671ea7e3321eb92a5 https://doi.org/10.1007/s12094-019-02213-9 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....7eabdbae4f23487671ea7e3321eb92a5 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 16993055 1699048X |
|---|